甲状腺眼病的治疗及治疗反应预测因素的研究进展  

Research Progress on the Treatment of Thyroid Eye Disease and the Predictors of Treatment Response

作　　者：蒋炫 龙健[1] 

机构地区：[1]重庆医科大学附属第一医院内分泌科,重庆

出　　处：《临床医学进展》2024年第12期660-664,共5页Advances in Clinical Medicine

摘　　要：甲状腺眼病(Thyroid eye disease, TED)是一种累及眼部的自身免疫性疾病。糖皮质激素是中至重度TED的首选药物治疗,治疗不佳者可能导致疾病进展,威胁患者视力,严重者可致残。全面了解TED的治疗方式及影响治疗效果的因素有助于评估疾病预后,尽早采取干预手段以避免患者出现严重的视力损害。本文结合近几年该方面的最新研究对此展开综述。Thyroid eye disease (TED) is an autoimmune disease involving the eye. Glucocorticoids are the preferred pharmacologic treatment for patients with moderate-to-severe TED. Inadequate treatment can lead to disease progression, potentially jeopardizing vision and resulting in disability in severe cases. A comprehensive understanding of the treatment modalities and factors affecting the outcome of TED is helpful in assessing the prognosis of the disease and in taking early interventions to prevent severe visual impairment. This article summarizes the latest research in this area in recent years.

关 键 词：甲状腺眼病 糖皮质激素 预测因素 

分 类 号：R73[医药卫生—肿瘤]